Gene expression profile and cancer-associated pathways linked to progesterone receptor isoform a (PRA) predominance in transgenic mouse mammary glands

María José Carlini1,2,4, María Sol Recouvreux3, Marina Simian3,5 and Maria Aparecida Nagai1,2*

Abstract

Background: Progesterone receptor (PR) is expressed from a single gene as two isoforms, PRA and PRB. In normal breast human tissue, PRA and PRB are expressed in equimolar ratios, but isoform ratio is altered during malignant progression, usually leading to high PRA:PRB ratios. We took advantage of a transgenic mouse model where PRA isoform is predominant (PRA transgenics) and identified the key transcriptional events and associated pathways underlying the preneoplastic phenotype in mammary glands of PRA transgenics as compared with normal wild-type littermates.

Methods: The transcriptomic profiles of PRA transgenics and wild-type mammary glands were generated using microarray technology. We identified differentially expressed genes and analyzed clustering, gene ontology (GO), gene set enrichment analysis (GSEA), and pathway profiles. We also performed comparisons with publicly available gene expression data sets of human breast cancer.

Results: We identified a large number of differentially expressed genes which were mainly associated with metabolic pathways for the PRA transgenics phenotype while inflammation-related pathways were negatively correlated. Further, we determined a significant overlap of the pathways characterizing PRA transgenics and those in breast cancer subtypes Luminal A and Luminal B and identified novel putative biomarkers, such as PDHB and LAMB3.

Conclusion: The transcriptional targets identified in this study should facilitate the formulation or refinement of useful molecular descriptors for diagnosis, prognosis, and therapy of breast cancer.

Keywords: Progesterone receptor, Isoforms, Transgenic mice, Mammary gland, Hyperplasia, Breast cancer, Gene expression profiling, Gene set enrichment analysis, Biomarker
Background
Estrogen and progesterone signaling via their receptors play important roles not only in normal mammary gland development but also in breast cancer progression [1, 2]. Gene expression profiling has revealed at least five subtypes of breast cancer: luminal A (LumA), luminal B (LumB), HER2, basal and normal [3, 4]. Importantly, the immunophenotypic evaluation, i.e., the analysis of markers by immunohistochemistry such as estrogen receptor (ER), PR, Ki67, HER2 and basal cytokeratins (CK 5/6, CK14) is a useful surrogate of the gene expression defined-subtypes [5].

PR is expressed from a single gene as two isoforms, PRA and PRB. The two isoforms are expressed at similar levels in the breast, but the ratio can be altered in human breast tumors, with the PRA isoform predominating [6]. Moreover, high PRA/PRB ratios predicted shorter disease-free survival in patients who received local therapy followed by adjuvant tamoxifen, indicating [7]. Furthermore, high PRA/PRB ratios predicted shorter disease-free survival in patients who received local therapy followed by adjuvant tamoxifen, indicating resistance to tamoxifen, underscoring the prognostic value of discriminating PR isoforms [7, 8]. Importantly, preclinical studies with murine and human tumors and ex vivo human breast cancer tissue culture assays showed that antiprogestin responsiveness in breast cancer is determined by the PRA/PRB expression ratio, specifically, an inhibitory effect of the antiprogestin mifepristone is only obtained in tumors with higher levels of PRA than PRB [9, 10].

In vitro, inducing a high PRA/PRB ratio in the T47D cell line conferred responsiveness to progestins to a set of genes involved in cellular metabolism and regulation of cell shape and adhesion. In accordance, progestin treatment resulted in reduced cell adhesion, which was significantly decreased even further when PRA was predominant [11]. Other studies aiming to determine the relative contributions of PR isoforms functions of PRA and PRB have employed cell lines engineered to express only a single PR isoform [12]. Due to common features, the mouse mammary gland is a useful model for normal human breast, and breast cancer [1] and transgenic mice allow exploring hormone receptor actions in the gland. Transgenic mice carrying either an additional A form of PR (PRA transgenics) or the B form of PR show abnormal mammary gland features [13]. In particular, mammary glands of PRA transgenics exhibit extensive lateral branching, ductal hyperplasia, a disorganized basement membrane and loss of cell-cell adhesion [13–15]. Studies using the molecular markers for transformation, as defined by Medina [16], revealed that these mammary glands contained at least two distinct populations of transformed epithelial cells. The ducts with normal histology contained cells resembling immortalized cells, while hyperplasias consisted of cells in later stages of transformation associated with early pre-neoplasias and exhibited increased epithelial cell proliferation [15]. Similarly, loss of coordinate expression of PRA and PRB occurs early in human breast cancer progression [17]. Therefore, evidence supports that misregulation of the PRA/PRB expression ratio can have major implications for mammary carcinogenesis.

In the present study, using the well characterized PRA transgenic mouse model, we sought to determine the full repertoire of target transcripts and pathways underlying the aberrant phenotype of mammary glands in PRA transgenics as compared with wild-type litter-mates in a relevant in vivo microenvironment under physiological hormone conditions. Further, using publicly available gene expression data sets of human breast cancer, we have explored the potential overlapping relevant pathways with breast cancer and identified novel putative biomarkers. Understanding the molecular context of deregulated PR action in the mammary gland may well accelerate the formulation of useful molecular descriptors for diagnosis, prognosis, and therapy of breast cancer.

Methods
Mice
Nulliparous adult FVB mice (20–25 weeks) were used in this study. The generation of PR-A transgenic mice, which carry an imbalance in the normal ratio of the two forms of PR by overexpression of the A form, has been previously described [13]. In brief, we used a binary transgenic system in which the GAL-4 gene, driven by the murine cytomegalovirus (CMV) promoter (CMV-GAL-4 mice), served as the transactivator of the PR-A gene, carrying four GAL-4-binding sites (UAS; UAS-PR-A mice). Crossing the CMV-GAL-4 mice with UAS-PR-A mice resulted in bigenic mice carrying additional PR-A gene [13]. The animals were housed in the Animal Care Division at the Institute of Oncology “Ángel H. Roffo” in an air-conditioned room at 22 °C under a 12-h light/dark cycle with access to food and tap water ad libitum and treated in accordance with the NIH Guide for Humane Use of Animals in Research.

Harvesting mammary gland RNA
Mice were euthanized by cervical dislocation, and mammary glands were harvested from all mice at diestrus, given that serum progesterone levels and the morphological grade, epithelial proliferation, and apoptosis in the mammary gland all peak at this stage [18]. A total of seven animals were used (3 wild-type, 4 PR transgenic).

In each case, a single abdominal gland was removed following excision of lymph nodes and immediately frozen in liquid nitrogen. Tissue was pulverized in a Thermo-vac tissue pulverizer (Thermovac Industries Corp.) at liquid nitrogen temperature. The resulting powder was transferred into tubes containing 1.5 ml of
Trizol reagent (Thermo Fisher Scientific Inc.) and homogenized by passing the lysate through sterile, disposable 21G needle 5 times twice. Following homogenization, samples were centrifuged at 12000×g for 10 min at 4 °C. The fatty layer above the supernatant was removed and discarded, and the cleared supernatant was transferred to a new tube. Total RNA was extracted according to manufacturer’s instructions, followed by additional column purification (RNeasy Mini Kit, Qiagen Inc.). We chose a reference-based 2-color microarray design given that it decreases intra- and inter-experimental variability by relating expression measurements of experimental RNA to a common reference, rather than relying on absolute signal intensity. At the same time, the use of spike-in controls allowed to monitor the system for linearity, sensitivity, and accuracy (https://www.genomics.agilent.com/files/Manual/Spike-in_Kit.pdf). RNA integrity was assessed using the RNA 6000 Nano Assay and Agilent 2100 Bioanalyzer (Agilent Technologies Inc.).

Microarray analysis
Labeled cRNA was prepared from 50 ng RNA using the Low Input QuickAmp Labeling Kit Two-Color and RNA Spike-In Kit for Two colors v4.0 (Agilent Technologies Inc.) according to manufacturer’s instructions, followed by RNeasy Mini Kit (Qiagen Inc.) purification. Experimental samples were labeled with Cy5 and Universal Mouse Reference RNA (Agilent Technologies Inc.) with Cy3. Dye incorporation and cRNA yield were checked with the NanoDrop Spectrophotometer (NanoDrop Technologies Inc.). Then, 300 ng of Cy5/Cy3-labeled cRNA was fragmented and prepared for hybridization using the Gene Expression Hybridization Kit (Agilent Technologies Inc.) following manufacturer’s instructions and hybridized to SurePrint G3 Mouse Gene Expression v2 8x60K (Agilent Technologies Inc.) for 17 h at 65 °C in a rotating hybridization oven. After hybridization, microarrays were washed for 1 min at room temperature with GE Wash Buffer 1 (Agilent Technologies Inc.) and 1 min with 37 °C GE Wash buffer 2 (Agilent Technologies Inc.) containing 0.005% Triton X-100. Slides were scanned immediately after washing using the G4900DA SureScan microarray scanner system, features were extracted with Agilent Feature Extraction Software (Agilent Technologies Inc.) and good quality control metrics were confirmed for all report files. Data analyses were conducted with GeneSpring GX software (Agilent Technologies Inc.). Input data was pre-processed by baseline transformation to the median of all samples. After grouping of replicates according to their respective experimental condition differential gene expression was statistically determined by unpaired T-test with significance set at p < 0.05. An unbiased grouping of samples was created only on the basis of their molecular profiles by unsupervised clustering analysis. Transcripts were subjected to hierarchical clustering with Euclidean distance metrics and average linkage using GeneSpring.

Gene ontology analysis
Statistically overrepresented GO categories within differentially expressed gene lists were determined using BiNGO (Biological Network GO) [19] and visualized using Cytoscape. The statistical test was the Hypergeometric test with Benjamini & Hochberg False Discovery Rate (FDR) correction and 0.05 significance level. GO annotation and ontology files were from the GO consortium (www.geneontology.org), and the reference set included all the genes on the microarray.

Gene set enrichment analysis
GSEA [20] was carried out by using the GSEA software, version 3.0, obtained from the Broad Institute (http://www.broadinstitute.org/gsea/downloads.jsp). Expression data sets (.GCT format), phenotype labels (.CLS format) and annotations (.CHIP format) were created according to GSEA specifications. We computed overlaps with the H (hallmark gene sets), C2 (curated gene sets) and C5 (GO gene sets) collections. The C2 collection analysis was divided for the subcollections cp (canonical pathways: Biocarta, KEGG, and Reactome) and CGP (chemical and genomic perturbations), the latter was filtered by the search “mammary OR breast” and “Mus musculus” and “Homo sapiens” organisms, resulting in a collection of 442 gene sets. Gene set permutations (to avoid the potential problem of a small sample size) were done 1000 times for each analysis using the weighted enrichment statistic and signal to noise metric. Gene sets that met the false discovery rate lower than 25% criterion were considered significant. When necessary, enrichment maps [21] were plotted to visualize GSEA analysis results and overcome gene set redundancy.

For comparison purposes, GSEA files were prepared for breast cancer gene expression data (METABRIC, [22, 23], downloaded from cBio portal [24, 25] using the PR+ samples in LumA and LumB subtypes, and the Basal and Her2+ subtypes compared with Normal. GSEA was computed with the H collection. The pathway list overlap between the significant pathways in PRA transgenics and the breast cancer subtypes was calculated with overlap stats program (http://www.nemates.org/MA/progs/overlap_stats.html) which calculates the significance of the overlap (P value) by using hypergeometric probability.
Kaplan-Meier curves
Kaplan-Meier plotter (http://kmplot.com/analysis/) was used to perform a meta-analysis based biomarker assessment. Relapse-free survival curves were generated with patients split according to the best cutoff values auto-selected by the tool, using only JetSet best probe sets, removing redundant probes and excluding biased arrays. P values are from log-rank test.

Results
Transcriptional changes in PRA transgenic mammary glands
To better understand the effects of PRA overexpression on breast cancer, we compared the expression profile in mammary glands of PRA transgenics with wild-type littermates using oligonucleotide microarray analysis. The expression signatures for wild-type and PRA transgenic mammary glands were strong enough to be recognized by unsupervised clustering (Fig. 1a). A volcano plot representing the distribution of the fold changes (FC) and P-values, showed that 401 of 56,344 probes were significantly (P < 0.01, unpaired t-test, FC ≥ 2) different in PRA transgenic mice as compared with wild-type (255 down and 92 up-regulated, Fig. 1b). Focusing on these most differentially expressed genes (DEG), we applied clustering across samples and genes, using the Euclidean distance metric and average-linkage and plotted a heat map, where the genes (columns) and samples (rows) are ordered by their corresponding hierarchical clusters (Fig. 1c). As expected, we observed robust gene clusters from replicate data sets.

Gene ontology analysis
DEGs were interrogated for their GO classes using BiNGO (Biological Network GO) to identify overrepresented functional themes, using the complete list of transcripts in the microarray as a reference set. We could not identify significantly enriched categories with this first approach. Therefore we used a less stringent cut-off (≥1.5 FC and P < 0.05) to define the DEG list. BiNGO mapping outputs are presented as Cytoscape

Fig. 1 a) Dendrogram depicting unsupervised clustering of array data for 4 PR-A transgenics and 3 wild-type samples. b) Volcano plot for differentially expressed genes (DEG). DEG appear above the green horizontal line (unpaired t-test, P < 0.01). Genes induced > 2-fold are on the right of the right green vertical line (red colored), and the ones repressed > 2-fold are on the left of the left green vertical line (blue colored). c) Heat map depicting the relative fold change in expression levels of the 401 transcripts that were differentially expressed by ≥2.0-fold (P < 0.01, 255 downregulated, blue and 92 upregulated, red) between the PRA transgenic and the wild-type group.
graphs (Fig. 2). For the upregulated genes, the anatomical structure development category amongst the biological processes was significantly overrepresented (corrected $P < 0.05$), suggesting an active remodeling process (Fig. 2a). As for downregulated genes (Fig. 2b), there were changes mainly at the plasma membrane, as indicated by over-representation of this cellular compartment (corrected $P < 0.01$). Consequently, the enriched cellular processes included transmembrane transport and cell adhesion (corrected $P < 0.001$).

Also, as an in silico approach to validate the microarray data generated in the present study, we compared our DEG data set with PR regulated genes identified in a previous study. Fifty-five genes of our list ($\geq 1.5$ FC and $P < 0.05$) had been previously identified as regulated by PR in a human breast cancer cell line model that allows controlled expression of PRA/PRB [26] (Table 1).

**Gene set enrichment analysis**

GSEA was performed for the PRA > wild-type comparison using C2 (curated gene sets), C5 (GO gene sets) and the H (hallmark gene sets) collections in MSigDB. We chose to interrogate the C2 collection to identify relevant pathways, C5 to confirm and extend our previous GO analysis and H collection for detecting specific biological processes, given that the latter was developed by a combination of automated approaches and expert curation and is more effective and accurate by reducing noise and redundancy [27].

The C2 collection (chemical and genomic perturbation -CGP- sub-collection) was limited to the specific context of the mammary gland, employing a search with the terms “mammary OR breast” in the MSigDB resource. Three gene sets were positively correlated with the PRA phenotype, including two sets of genes within amplicons 16p13 and 22q13 identified in a study of 191 breast tumor samples [28]; the corresponding enrichment plots are depicted in Fig. 3a. Of note, amplicon 16p13 is one of the most frequent and well-characterized amplicons in human breast cancer. A high number of gene sets (115) were correlated with the wild-type phenotype. To overcome gene-set redundancy and help in the interpretation we used enrichment map visualization and three approximately homogeneous clusters were manually identified as: (i) gene sets related to mammary gland morphological changes or breast cancer subtypes; (ii) gene sets related to estradiol or tamoxifen response and (iii) gene sets comprising targets of polycomb complexes (Fig. 3b).

Finally, analysis of the H collection revealed eight pathways positively correlated with the PRA phenotype, including metabolism-related pathways (cholesterol homeostasis, metabolism of fatty acids, oxidative phosphorylation, glycolysis and mTORC1 signaling), as well as genes important for mitotic spindle assembly and a subgroup of genes regulated by MYC-version 2 (v2). Nineteen gene sets were positively correlated with the wild-type phenotype (downregulated in PRA). Four gene sets comprised genes involved in inflammation-related pathways. The remaining included hallmark pathways of apoptosis and UV response, epithelial-to-mesenchymal transition (EMT) and TGF-beta signaling, and the developmental hedgehog signaling pathway. The complete list of pathways is presented in Table 2.

The results of querying the C2.CP Reactome and KEGG pathways subcollections reinforced the findings obtained with the Hallmark collection. Interestingly, the steroid hormone biosynthesis KEGG pathway correlated with PRA downregulated genes (FDR = 0.106). Also, as expected, C5 GO collection provided similar results as BinGO, thus cross-checking our first analysis.

**Overlapping hallmark pathways in human breast cancer subtypes**

It has been reported that the distinct stages of human breast cancer progression premalignant, premalignant and invasive have remarkable similar transcriptomes with the
most significant gene expression changes taking place in the early stages [29, 30]. Porter et al. reported that the most dramatic changes occurred at the normal to ductal carcinoma in situ (DCIS) transition, including the uniform downregulation of 34 genes; while no “in situ” or “invasive” signature was clear [30]. Further, aberrant PR isoform ratios are detected early in the progression of breast lesions from the normal state to malignancy [17]. In view of this, we aimed to assess to what extent the key pathways described above for the PRA > wild-type comparison (Table 2) were similarly enriched in human breast cancer tumor samples of different subtypes. To this end, we determined the enriched pathways for breast cancer subtypes using the transcriptomic data from a much larger data set (METABRIC, [22, 23]) downloaded from cBioPortal [24, 25]. We run GSEA analysis using the hallmark collection with this data, comparing the subtypes mainly positive for PR, LumA and LumB, with normal. Then, we calculated the overlap of the obtained pathways with those identified in our study (Table 3). Of note, we observed a significant overlap of upregulated pathways between the mammary glands of PR-A transgenic and the human LumB breast cancer subtype. Further, the downregulated pathways overlapped significantly with both LumA and LumB subtypes, while no overlapping was observed with the pathways associated with the non-PR expressing subtypes Her2 and Basal (data not shown). To narrow down further analysis we focused on the most upregulated and downregulated pathways: oxidative phosphorylation and TNFA signaling via NFKB, respectively to study the participating genes in more detail.

**Genes from the oxidative phosphorylation pathway**

When comparing genes obtained by GSEA statistic computation and Genespring (which we used to obtain our

---

**Table 1** Differentially expressed genes in our gene set supported by previous data [26]

| Upregulated (12) | Downregulated (43) |
|------------------|---------------------|
| CACNG7, DOCK4, FAM46A, GLIS3, KDM4A, NEBL, NLRP3, ODC1, PITX2, STEAP2, TLR4, TOM1L2 | ATP8B1, BTNL2, CAV3, CDC14A, DDT4, ETS1, FAM84A, FDACS, GIGYF2, GPR39, HDAC9, IER3, IL7R, KLF2, KR1, LAMB3, LIMCH1, LYPD1, MALT1, MAMLD1, NAV2, NEK10, NRR11, PDH17, PDE1C, PDE4B, PDE4DP, PDK4, PDZD2, RGS7, ROR1, SDK1, SH3TC2, SH5A3, SLC16A9, SNCAP1, SOC51, SYT12, TACC2, TNS1, TSGA10, TTC39A, VAMP1, ZFYVE28 |

---

**Fig. 3 a)** Enrichment plots showing the correlation of gene sets from breast cancer amplicons 16p13 (FDR q-value 0.106) and 22q13 (FDR q-value 0.101) with the PRA phenotype. Profile of the running enrichment score and positions of gene set members on the rank-ordered list (upregulation or downregulation of genes in PRA transgenics relative to their expression in wild-type). **b)** Enrichment map visualization of gene-sets correlating with down regulated genes in PRA transgenics showing manually identified clusters defined as (i) gene sets related to mammary gland morphological changes or breast cancer subtypes; (ii) gene sets related to estradiol or tamoxifen response and (iii) gene sets comprising targets of polycomb complexes. In the similarity network node size represents the number of genes in the gene-set; edge thickness is proportional to the overlap between gene-sets and the enrichment score is mapped to the node color as a color gradient, in this case blue (high enrichment in wild-type).
Table 2 Significant up or downregulated pathways of the hallmark MSigDB collection in PRA transgenic mammary glands, according to GSEA analysis with FDR < 25%

| Pathways                              | NES  | NOM p-val | FDR q-val |
|---------------------------------------|------|-----------|-----------|
| **Upregulated**                       |      |           |           |
| OXIDATIVE PHOSPHORYLATION             | 1.90 | 0.00      | 0.003     |
| ADIPOGENESIS                          | 1.40 | 0.01      | 0.139     |
| MITOTIC SPINDLE                       | 1.40 | 0.01      | 0.124     |
| GLYCOLYSIS                            | 1.30 | 0.05      | 0.219     |
| CHOLESTEROL HOMEOSTASIS               | 1.30 | 0.12      | 0.224     |
| DNA REPAIR                            | 1.20 | 0.10      | 0.259     |
| MTORC1 SIGNALING                      | 1.20 | 0.08      | 0.234     |
| MYC TARGETS V2                        | 1.20 | 0.17      | 0.231     |
| FATTY ACID METABOLISM                 | 1.20 | 0.15      | 0.221     |
| **Downregulated**                     |      |           |           |
| TNFA SIGNALING VIA NFkB               | −2.20| 0.00      | 0.000     |
| IL6 JAK STAT3 SIGNALING               | −2.00| 0.00      | 0.001     |
| ALLOGRAFT REJECTION                   | −1.90| 0.00      | 0.003     |
| INFLAMMATORY RESPONSE                 | −1.80| 0.00      | 0.003     |
| TGF BETA SIGNALING                    | −1.70| 0.00      | 0.005     |
| KRAS SIGNALING UP                     | −1.60| 0.00      | 0.025     |
| APOPTOSIS                             | −1.60| 0.00      | 0.025     |
| EPITHELIAL MESENCHYMAL TRANSITION     | −1.60| 0.00      | 0.023     |
| UV RESPONSE DIN                       | −1.60| 0.00      | 0.020     |
| HEDGEHOG SIGNALING                    | −1.60| 0.04      | 0.025     |
| INTERFERON GAMMA RESPONSE             | −1.50| 0.01      | 0.034     |
| IL2 STATS SIGNALING                   | −1.40| 0.02      | 0.100     |
| COMPLEMENT                             | −1.30| 0.04      | 0.125     |
| KRAS SIGNALING DOWN                   | −1.30| 0.07      | 0.212     |
| HYPOXIA                               | −1.30| 0.06      | 0.205     |
| APICAL SURFACE                        | −1.30| 0.18      | 0.214     |
| APICAL JUNCTION                       | −1.30| 0.07      | 0.203     |
| PI3K AKT MTOR SIGNALING               | −1.20| 0.13      | 0.239     |
| G2M CHECKPOINT                        | −1.20| 0.11      | 0.248     |

NES normalized enrichment score, NOM p-val nominal p-value, FDR q-val false discovery rate q-value

Table 3 Significantly up and downregulated hallmark pathways for breast cancer subtypes and statistical significance of the overlap with those found for PRA transgenics

|                  | Number of significant pathways in the set (out of 50 total) | Number of overlapping pathways | P value   |
|------------------|-------------------------------------------------------------|--------------------------------|-----------|
| **Upregulated**  |                                                              |                                |           |
| PRA Transgenic   | 8                                                           | 3                              | 0.188     |
| Luminal A        | 10                                                          | 3                              | 0.043     |
| Luminal B        | 15                                                          | 5                              |           |
| **Downregulated**|                                                              |                                |           |
| PRA Transgenic   | 19                                                          | 16                             | 0.002     |
| Luminal A        | 28                                                          | 16                             | 7.10E-04  |
| Luminal B        | 24                                                          | 15                             |           |

Bolded values indicate statistically significant overlap (i.e., p-value < 0.05)
list of DEG) we found only two genes from the oxidative phosphorylation pathway overlapping between PRA transgenics and LumB subtype that were in both lists (Table 4 and Additional file 1: Table S1 for a complete list of the genes identified by GSEA analysis). However, one of these (TIMM9) was not significantly modulated in the breast cancer dataset, neither had an impact in patient survival (Additional file 1: Figure S1). On the other hand, PDHB (Pyruvate dehydrogenase E1 component subunit beta, mitochondrial) upregulated in PRA transgenics (FC 1.43, \(P = 0.02\)) although with a FC at the borderline of our criteria (\(\geq 1.5\) FC and \(P < 0.05\)) was not only upregulated in LumB subtype from the METABRIC study, as expected from GSEA analysis, but also in LumA subtype (Fig. 5a). Moreover, we explored the potential prognostic value of PDHB using Kaplan Meier plotter [31] and found that high PDHB expression correlated with poor relapse-free survival for patients with LumA and LumB tumor subtypes (Fig. 4b).

**Genes from the TNFA signaling via NFKB pathway**

For this pathway, we found several genes from our original list overlapping with the LumA and LumB phenotypes (Table 4 and Additional file 1: Table S2 for a complete list of the genes identified by GSEA analysis).

| Gene symbol | FC  | \(P\)-value |
|-------------|-----|-------------|
| TIMM9       | 1.8 | 0.019       |
| PDHB        | 1.4 | 0.024       |
| IL7R        | -4.6| 0.036       |
| KYNU        | -3.1| 0.006       |
| EGR3        | -2.9| 0.029       |
| EGR1        | -2.9| 0.037       |
| MSC         | -2.4| 0.022       |
| LAMB3       | -2.3| 0.001       |
| BMP2        | -2.0| 0.019       |
| PDE4B       | -2.0| 0.018       |
| NR4A1       | -1.9| 0.032       |
| FOSB        | -1.9| 0.011       |
| KLF2        | -1.8| 0.041       |
| PMEPA1      | -1.8| 0.043       |
| JUNB        | -1.6| 0.009       |
| CD44        | -1.6| 0.035       |
| CCL2        | -1.5| 0.001       |
| IER2        | -1.5| 0.047       |
| ZFP36       | -1.5| 0.029       |

With the only exception of CD44, when analyzing the expression data for these genes in the METABRIC study, they were downregulated in the LumA and/or LumB phenotypes, compared with normal as it was expected (9/17 downregulated in both subtypes, 1/17 only in LumA, 6/17 only in LumB). Fig. 5a shows the plot for LAMB3 as an example (see Additional file 1: Figure S2 for the remaining genes). The potential prognostic value of these genes was also assessed, showing promising results for many of them. The Kaplan Meier plots for LAMB3, indicating that low expression was correlated with poor relapse-free survival for patients with LumA, LumB and Basal tumor subtypes (Fig. 4b).

**Discussion**

Changes in the native ratio of A to B isoforms of PR have major implications to normal mammary gland biology and also tumorigenesis. For this reason, several groups have previously used expression profiling to identify genes associated with PRA:PRB imbalanced ratio in breast cancer cell lines [11, 26, 32, 33]. However, none have explored the transcriptional changes of preneoplastic lesions that are associated with PRA:PRB imbalance and tumor progression in an in vivo model. In this study, we took advantage of PRA transgenics, a previously described transgenic mouse model where PRA isoform is predominant. Using oligonucleotide microarray technology, we identified the complete repertoire of genes that are altered in expression in the abnormal mammary glands of PRA transgenics and characterized the associated pathways. Importantly, several of the DEG identified in this study (Table 1) had been previously reported as PR targets [26].

Based on the distinct transcriptomics of PRA transgenics, we first identified by GO analysis an enrichment in the biological processes anatomical structure development and cell adhesion for upregulated and downregulated genes, respectively (Fig. 2a and b). This is in accordance with the key morphological features of PRA transgenic mammary glands, including extensive lateral branching, the disruption in the organization of the basement membrane and a decrease in cell–cell adhesion [13]. The influence of PRA:PRB ratio in cell adhesion has also been described in PR-positive T-47D breast cancer cells in which PRA can be induced to result in PRA predominance. Cell adhesion of T-47D cells was decreased upon progestin treatment and reduced even further with PRA predominance [11]. Another enriched biological process identified in this study for
downregulated genes was transmembrane transport, and the cell membrane itself was enriched amongst the cellular compartments. Similarly, Richer et al. found an extensive number of genes involved in membrane-initiated events that were regulated by PR isoforms in response to progesterone, thus stressing the membrane as an important target of progesterone action [33]. Also, more recently, SLC- mediated transmembrane transport was found amongst enriched pathways in human breast PRA high tumors as compared to PRB high tumors [10].

Then, we used GSEA to identify pathways and unifying themes. The GSEA method focuses on gene sets rather than a handful of high scoring genes at the top and bottom (which can suffer from arbitrary cutoff regarding fold-change or significance) giving more reproducible and easy to interpret results [20]. When necessary, we plotted enrichment maps of gene sets to aid interpretation [21]. Interestingly, we found a positive correlation of PRA transgenics with gene sets comprising amplicons previously identified in human breast cancer (Fig. 3a). One example is amplicon 16p13, which was previously correlated

Then, we used GSEA to identify pathways and unifying themes. The GSEA method focuses on gene sets rather than a handful of high scoring genes at the top and bottom (which can suffer from arbitrary cutoff regarding fold-change or significance) giving more reproducible and easy to interpret results [20]. When necessary, we plotted enrichment maps of gene sets to aid interpretation [21]. Interestingly, we found a positive correlation of PRA transgenics with gene sets comprising amplicons previously identified in human breast cancer (Fig. 3a). One example is amplicon 16p13, which was previously correlated

Then, we used GSEA to identify pathways and unifying themes. The GSEA method focuses on gene sets rather than a handful of high scoring genes at the top and bottom (which can suffer from arbitrary cutoff regarding fold-change or significance) giving more reproducible and easy to interpret results [20]. When necessary, we plotted enrichment maps of gene sets to aid interpretation [21]. Interestingly, we found a positive correlation of PRA transgenics with gene sets comprising amplicons previously identified in human breast cancer (Fig. 3a). One example is amplicon 16p13, which was previously correlated

Then, we used GSEA to identify pathways and unifying themes. The GSEA method focuses on gene sets rather than a handful of high scoring genes at the top and bottom (which can suffer from arbitrary cutoff regarding fold-change or significance) giving more reproducible and easy to interpret results [20]. When necessary, we plotted enrichment maps of gene sets to aid interpretation [21]. Interestingly, we found a positive correlation of PRA transgenics with gene sets comprising amplicons previously identified in human breast cancer (Fig. 3a). One example is amplicon 16p13, which was previously correlated

Then, we used GSEA to identify pathways and unifying themes. The GSEA method focuses on gene sets rather than a handful of high scoring genes at the top and bottom (which can suffer from arbitrary cutoff regarding fold-change or significance) giving more reproducible and easy to interpret results [20]. When necessary, we plotted enrichment maps of gene sets to aid interpretation [21]. Interestingly, we found a positive correlation of PRA transgenics with gene sets comprising amplicons previously identified in human breast cancer (Fig. 3a). One example is amplicon 16p13, which was previously correlated
with luminal breast cancer subtype and comprises effector proteins such as proteases [28]. For genes downregulated in PRA transgenics, we identified three clusters based on the enrichment map (Fig. 3b). Not surprisingly, one cluster (ii) included gene sets related to mammary gland morphological changes or breast cancer subtypes. For example, a set comprising genes downregulated in ductal carcinoma vs normal ductal breast cells identified by laser microdissection and microarray analysis [34] and another set of genes that were downregulated in HMLE cells (immortalized nontransformed mammary epithelial) cells after loss of function of E-cadherin (CDH1) achieved by RNAi knockdown or by expression of a dominant-negative form [35]. Of note, mammary glands of PRA transgenics exhibited diminished E-cadherin in a disorganized pattern [13]. Another region in the map (ii) clustered gene sets related to estradiol or tamoxifen response like one set of genes downregulated in breast cancer SUM44/LCCTam cells resistant to 4-hydroxytamoxifen relative to the parental sensitive cells [36]. Importantly, in PR-positive breast cancer patients who received local therapy followed by adjuvant tamoxifen, high PRA:PRB ratios predicted shorter disease-free survival, indicating resistance to tamoxifen [7].

Our third (iii) identified cluster included gene sets comprising targets of polycomb complexes. In particular, Polycomb Repression Complex 2 (PRC) targets that possess H3K27me3 mark in their promoters and are bound by SUZ12 and EED Polycomb proteins [37]. This suggests that PRC2 may be an upstream regulator accounting for the high number of downregulated genes in PRA transgenics. Interestingly, H3K27me3 mark has been positively associated with the LumA subtype compared to all other subtypes in a cohort of breast cancer patients [38].

We then performed GSEA analysis using the Hallmark collection (Table 2). We found positive enrichments mainly in metabolic pathways for the PRA transgenics phenotype. Changes in metabolism during tumorigenesis are well known. Our analysis suggests metabolic plasticity, as oxidative phosphorylation in addition to glycolysis were significantly enriched, and this adaptability may be important as tumorigenesis progresses [39]. Pathways negatively correlating with PRA transgenics phenotype pointed to an anti-inflammatory effect. PR action has been linked previously with inhibition of inflammatory response in breast cancer cells [40] and myometrial cells [41]. However, the uterine phenotype of PRA transgenics included endometritis and pelvic inflammatory disease (together with hyperplasia) [42], therefore effects on inflammation may be context-dependent in PRA transgenics. Recently, Cai et al. analyzed gene expression from four distinct stages of mammary tumor progression using the MMTV-PyMT mouse model and found similar enriched hallmark pathways amongst up and downregulated genes in the hyperplasia stage [43].

Conclusion

Further characterization of these and other genes identified in the present study would greatly increase our understanding of the early tumorigenic events associated with high PRA:PRB ratio and the underlying biological mechanisms and may provide new prognostic markers for breast cancer.

Additional files

**Additional file 1: Table S1.** Provides a complete list of the genes identified by GSEA analysis contributing to the upregulated oxidative phosphorylation pathway in both PRA transgenics and LumB breast cancer subtype. Figure S1. Provides TIMM9 expression, from the oxidative phosphorylation pathway, in samples from the METABRIC study, classified by subtype and relapse-free survival curves according to TIMM9 expression for the luminal breast cancer subtypes. Table S2. Provides a complete list of the genes identified by GSEA analysis contributing to the downregulated TNFA signaling via NFKB pathway in PRA transgenics, LumA and LumB breast cancer subtypes. Figure S2. Provides expression of genes, other than LAMB3, from the TNFA signaling through NFKB pathway in samples from the METABRIC study, classified by subtype. Figure S3. Provides relapse-free survival according to expression of the genes presented in Figure S2, for the luminal breast cancer subtypes. (PDF 5906 kb)
Abbreviations
BiNGO: Biological network gene ontology; DEG: differentially expressed genes; ER: estrogen receptor; FC: fold changes; GO: Gene ontology; GSEA: Gene set enrichment analysis; LAMB3: laminin subunit beta 3; LumA: Luminal A; Lum: Luminal B; PDHB: Pyruvate dehydrogenase E1 component subunit beta, mitochondrial; PR: Progesterone receptor; PRA: Progesterone receptor isoform A

Funding
This study was supported by Fundación de Armapa a Pesquisa do Estado de São Paulo (FAPESP) research grant 2015/10208–3 and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) 303134/2013–5 to M.A.N.; FAPESP 2014/13470–8 postdoctoral grant to M.J.C.; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) PIP 11220150100155CO to M.S. and 2013–2018 CONICET doctoral Fellowship to M.S.R. The funding body approved the study design, the plans for sample collection and data analysis before releasing the funds. FAPESP 2014/13470–8 also received a progress report during the study term and a final report at the end of the study term. The funding body played no role in the interpretation of data or writing of the manuscript.

Availability of data and materials
The datasets generated and/or analysed during the current study are available in the Gene Expression Omnibus (GEO) repository. The data was deposited to the NCBI GEO database under the GEO accession GSE112742 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE112742).

Authors’ contributions
Conceived and designed the experiments: MJC, MSR. Analyzed the data: MJC. Contributed reagents/materials/analysis tools: MJC, MSR, MAN. Wrote the paper: MJC, MAN. All authors read and approved the manuscript.

Ethics approval
The study protocol was approved by the Ethics Committee of Faculdade de Medicina da Universidade de São Paulo (391/14). This article adheres to the ARRIVE guidelines (http://www.nc3rs.org.uk/page.asp?id=1357) for the reporting of animal experiments.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Discipline of Oncology, Department of Radiology and Oncology, Faculty of Medicine, University of São Paulo, São Paulo, SP 01246-905, Brazil.
2Laboratory of Molecular Genetics, Center for Translational Research in Oncology, Cancer Institute of São Paulo, São Paulo, SP 01246-000, Brazil.
3Instituto de Oncología “Angel H. Roa”, Av. San Martin 5481, C1417DTB Ciudad Autónoma de Buenos Aires, Argentina. *Present address: Department of Pharmacological Sciences, kahn School of Medicine at Mount Sinai, 1468 Madison Avenue, New York, NY 10029, USA. 1Present address: Instituto de Nanosistemas, Universidad Nacional de San Martin, Av. 25 de Mayo 1021, 1650 San Martin, Provincia of Buenos Aires, Argentina.

Received: 14 November 2017 Accepted: 24 May 2018 Published online: 25 June 2018

References
1. Briskin C. Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer. 2013;13(6):385–96.
2. Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol. 20185;462:14. https://doi.org/10.1016/j.mce.2017.08.011. Epub 2017 Aug 26. Review. PubMed PMID. 28851667.
3. Sotie T, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98(19):10869–74.
4. Perou CM, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. Aug. 1999;96(16):9221–7.
5. Cuzick J, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer. J Clin Oncol. 2011;29(32):4273–8.
6. Graham JD, et al. Characterization of progesterone receptor a and B expression in human breast cancer. Cancer Res. 1995;55(21):5063–8.
7. A Hopp T, et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004;10(8):2751–60.
8. Mote PA, et al. Progesterone receptor a predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Res Treat. 2015;151(2):309–18.
9. Wargon V, et al. Progesterin and antiprogesterone responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the. 2014:01–13.
10. Rojas PA, et al. Progesterone receptor isoform ratio: a breast Cancer prognostic and predictive factor for Antiprogesterin responsiveness. JNCI J Natl Cancer Inst. Jul. 2017;109(7).
11. Graham JD, Yager ML, Hill HD, Byth K, O’Neill GM, Clarke CL. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol. 2005;19(1):2713–35.
12. Chalbos D, Galtier F. Differential effect of forms a and B of human progesterone receptor on estradiol-dependent transcription. J Biol Chem. 1994;269(37):23007–12.
13. Shyamala G, Yang X, Silberstein G, Barcellos-Hoff MH. Altered ovarian estrogen and progesterone receptors cing an imbalance in the native ratio of a to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc Natl Acad Sci U S A. 1998;95(2):696–71–1.
14. Chou Y-C, Uehara N, Lowry JR, Shyamala G. Mammary epithelial cells of PR-A transgenic mice exhibit distinct alterations in gene expression and growth potential associated with transformation. Carcinogenesis. 2003;24(4):403–9.
15. Simian M, Bissel MJ, Barcellos-Hoff MH, Shyamala G. Estrogen and progesterone receptors have distinct roles in the establishment of the hyperplastic phenotype in PR-A transgenic mice. Breast Cancer Res. 2009;11(5):R72.
16. Medina D. Biological and molecular characteristics of the premalignant mouse mammary gland. Biochim Biophys Acta. 2002;1603:9–1.
17. Mote PA, Bartow S, Tran N, Clarke CL. Loss of co-ordinate expression of progesterone receptors has distinct roles in the establishment of the hyperplastic phenotype. Carcinogenesis. 2003;24(3):403–9.
18. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
19. Neill GM, Clarke CL. Altered regulation of breast Cancer-associated genes by progesterone receptor 2 immunohistochemical score and comparison with the. 2011;29(32):4273–8.
20. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One. 2010;5(11)
21. Curtis C, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.
22. Perez A, et al. The somatic mutation profiles of 2,433 breast cancers refines tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
23. Carlini D, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discov. 2012;2(5):401–6.
24. Jiao Q, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
25. Khan J, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
26. Noonan P, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
27. Khan J, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
28. Khan J, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
29. Khan J, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
30. Khan J, et al. “Integrative analysis of complex Cancer genomics and clinical profiles using the cBioPortal,” Sci Signal, Vol. 6, no. 269, p. p11-p11, 2013.
27. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database Hallmark gene set collection. Cell Syst. 2015;1(6):417–25.
28. Nkoloki Y, et al. Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res. 2008;68(22):9532–40.
29. Ma X-L, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci. 2003;100(10):5974–9.
30. Porter D, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res. 2003;1(5):362–75.
31. Szász AM, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(51):49322–33.
32. Jacobsen BM, a Schittone S, Richer JK, Horwitz KB. Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol. 2005;19(3):574–87.
33. Richer JK, Jacobsen BM, Manning NG, Abel MG, Wolf DM, Horwitz KB. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem. 2002;277(1):5209–18.
34. Turashvili G, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7(1):55.
35. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008;68(10):3645–54.
36. Riggins RB, et al. ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer. Cancer Res. 2008;68(21):8908–17.
37. Ben-Porath I, et al. An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507.
38. Healey MA, et al. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses’ Health Study. Breast Cancer Res Treat. 2014;147(3):639–51.
39. Simões RV, et al. Metabolic plasticity of metastatic breast Cancer cells: adaptation to changes in the microenvironment. Neoplasia. 2015;17(8):671–84.
40. Hardy DB, Janowski BA, Chen C-C, Mendelson CR. Progesterone receptor inhibits aromatase and inflammatory response pathways in breast Cancer cells via ligand-dependent and ligand-independent mechanisms. Mol Endocrinol. 2008;22(8):1812–24.
41. D. B. Hardy, B. a Janowski, D. R. Corey, and C. R. Mendelson, “Progesterone receptor plays a major antinflammatory role in human myometrial cells by antagonism of nuclear factor-kappaB activation of cyclooxygenase 2 expression,” Mol Endocrinol, vol. 20, no. 11, pp. 2724–2733, 2006.
42. Fleisch WC, Chou YC, Cardiff RD, Asaithambi A, Shyamala G. Overexpression of progesterone receptor a isoform in mice leads to endometrial hyperplasia, hyperplasia and atypia. Mol Hum Reprod. 2009;15(4):241–9.
43. Cai Y, et al. Transcriptomic dynamics of breast cancer progression in the MMTV-PyMT mouse model. BMC Genomics. 2017;18(1):185.